Label-Free Detection Market worth $1,708.23 Million by 2018

Tuesday 13 May 2014, Amsterdam

The “Label-Free Detection Market by Technology (Bio-layer interferometry, Optical waveguide grating technology, Surface Plasmon resonance), Consumables & Instruments, Applications (Lead Generation, Binding Kinetics), End user - Global Forecasts & Trends to 2018” report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global label-free detection market along with the estimates and forecasts of the revenue and share analysis.

This report studies the global label-free detection market over the forecast period of 2013 to 2018. This market is valued at an estimated $1,708.23 million in 2013.

The report segments this market by technology, application, product, end user, and geography. The technology segments included in this report are bio-layer interferometry (BLI), cellular dielectric spectroscopy, optical waveguide grating technology (OWG), surface plasmon resonance (SPR), and other technologies. Of these, the surface plasmon resonance technology segment commanded the largest share of the global label-free detection market in 2013 and is also poised to grow at the healthy CAGR between 2013 and 2018. However, bio-layer interferometry segment is will grow at the highest CAGR between 2013 and 2018. The advantage of not using any labels or reporter molecules for detection along with increasing application of biomolecular interaction analysis in drug discovery are driving the growth of this technology segment.

The application segments included in this report are binding kinetics, binding thermodynamics, endogenous receptor detection, hit confirmation, lead generation, and other application segments. The binding kinetics application segment commanded the largest share of the global label-free detection market in 2013, while the hit confirmation segment is poised to grow at the highest CAGR between 2013 and 2018. The binding kinetic studies measure drug residence time, which are important for predicting clinical outcome of drug candidates. As such, the development in drug discovery will boost the binding kinetics studies and drive the label-free detection market.

The product segments in this report are instruments and consumables. Of these, the instrument segment commanded the largest share of the global label-free detection market in 2013 and is also poised to grow at the healthy CAGR between 2013 and 2018. Enhanced instrumentation makes it possible for pharmaceutical and biotechnology companies to streamline and simplify laboratory workflows, improve productivity and leads to reduction in the costs. Increasing adoption of label-free detection technologies in drug discovery will boost the growth of instruments in the forecast period.

The end-user segments included in this report are pharmaceutical and biotech companies, academic research institutes, contract research organization and other end users. Of these, the pharmaceutical & biotech companies end-user segment commanded the largest share of the global label-free detection market in 2013, while the CRO segment is poised to grow at the highest CAGR between 2013 and 2018. Label-free detection is rapidly gaining increased acceptance as an R&D tool in pharmaceutical and biotech industries and academic research for studying molecular interactions without the use of labels. Pharmaceutical and biotechnology companies widely use the label-free detection technology for their drug-discovery programs. This growth will be attributed to the increasing pharmaceutical outsourcing and increase in drug discovery research.

Based on geography, the global label-free detection market is segmented into geographic segments of Asia, Europe, North America, and the Rest of the World (RoW). Asia is segmented into regional segments of China, India, Japan and Rest of Asia. Europe is segmented into Germany, France, Italy, Spain, the U.K., and the Rest of Europe North America is segmented into the Canada and U.S., while the regional segments in Rest of World are Latin America, Middle East & Africa, and Pacific.

Label-free detection is a very well accepted drug discovery tool in the pharmaceutical & biotech industry and academic research. It helps in the investigation of biomolecular interactions without auto-fluorescent, spatial-interference, or quenching effects of labels. Increasing drug discovery programs by pharmaceutical companies and academic institutes will drive the growth of this market between 2013 and 2018. However, increasing market consolidation and high cost of instruments and consumables will restrain the growth of this market

The major players in the label-free detection market are Ametek, Inc. (U.S.), Attana AB (Sweden), Bio-Rad Laboratories, Inc. (U.S.), BiOptix (USA), Corning, Inc. (U.S.), Danaher Corporation (U.S.), General Electric Corporation (U.S.), Pall Corporation (U.S.), PerkinElmer (U.S.), Roche (Switzerland), and X-BODY Bioscience (U.S.).